TransportPDB: Center for the X-ray Structure Determination of Human Transporters
TransportPDB: Center for the X-ray Structure Determination of Human Transporters
批准号:
8715818
负责人:
GEOFFREY A CHANG
金额:
$230.33万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2015-06-30
关键词:
AddressAutomobile DrivingBiological AssayBiologyBiomedical ResearchCell membraneCellsCloningCodon NucleotidesCommunitiesComplexCrystallizationDataData CollectionDatabasesDetergentsDevelopmentDiseaseEngineeringFamilyGoalsHereditary DiseaseHomology ModelingHumanIntegral Membrane ProteinLaboratoriesMammalian CellMediatingMembrane ProteinsMethodsMolecularMulti-Drug ResistanceOrthologous GenePichiaProcessPropertyProtein Structure InitiativeProteinsResolutionResourcesRoentgen RaysSolubilityStructureSynthetic GenesSystemTechniquesTechnologyTherapeuticTranslationsUp-Regulationbasebiophysical propertiesdetectorexperienceflexibilityinstrumentationmemberneoplastic cellprotein foldingprotein structurescreeningsuccesstoolweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The passage of virtually every molecule across the cell membrane is mediated by a class of proteins called transporters. Transporters are vital to the biology of all cells and a variety of diseases occur when these processes are perturbed or disrupted, as in several genetic disorders or the up-regulation of multidrug resistance transporters by tumor cells. The availability of high resolution structures of human transporters is essential to define the molecular structural basis of their mechanisms. We propose to establish a center for membrane protein structure determination, TransportPDB, with the objective of developing a comprehensive and efficient approach for pursuing the high-resolution x-ray crystal structures of 521 transporters in 48 families presently identified in humans and other targets from PSI-biology centers. For this purpose and to address the objectives of the PSI, we have the following specific aims:
A1. An efficient pipeline will be established based on proven technologies and using our experience successfully crystallizing and solving the x-ray structures of integral membrane proteins. This pipeline will be based on several key principles: (a) target prioritization based on disease relevance and completing the protein-fold space coverage of human transporters, (b) the exclusive use of eukaryotic expression systems (Pichia pastoris and 293S mammalian cells) that have proven to deliver functional protein suitable for crystallization, (c) the cloning of constructs based on synthetic genes optimized for expression in both expression systems, and (d) using state-of-the-art data collection techniques for modestly diffracting crystals. The funnel-like organization will enable screening hundreds of human transporter targets and their close mammalian orthologs, driving towards the goal of successfully obtaining their x-ray crystal structures.
A2. High-throughput methods and technology will be developed for functional and biophysical characterization of targets to rapidly identify conditions that maintain protein stability and function leading towards higher quality and better diffracting human transporter crystals. New crystal mounting methods, together with micro-beam/rastering technology and increased sensitivity in data collection (PILATUS detector), will be implemented that could be decisive for modestly diffracting membrane protein crystals.
A3. Establish a resource for structural and functional data and other materials useful to the scientific community, including x-ray crystal structures of human transporters, codon-optimized clones, detergent solubilization conditions and corresponding stability properties of each target and homology models.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Directed evolution of P-glycoprotein cysteines reveals site-specific, non-conservative substitutions that preserve multidrug resistance.
P-糖蛋白半胱氨酸的定向进化揭示了保持多药耐药性的位点特异性、非保守性取代。
DOI:
10.1042/bsr20140062
发表时间:
2014
期刊:
Bioscience reports
影响因子:
4
作者:
[Swartz,DouglasJ, Mok,Leo, Botta,SriK, Singh,Anukriti, Altenberg,GuillermoA, Urbatsch,InaL]
通讯作者:
Urbatsch,InaL
DOI:
10.1371/journal.pone.0022577
发表时间:
2011
期刊:
PloS one
影响因子:
3.7
作者:
[Bai J, Swartz DJ, Protasevich II, Brouillette CG, Harrell PM, Hildebrandt E, Gasser B, Mattanovich D, Ward A, Chang G, Urbatsch IL]
通讯作者:
Urbatsch IL
P-glycoprotein is fully active after multiple tryptophan substitutions.
P-糖蛋白在多次色氨酸取代后具有完全活性。
DOI:
10.1016/j.bbamem.2012.12.005
发表时间:
2013
期刊:
Biochimica et biophysica acta
影响因子:
--
作者:
[Swartz,DouglasJ, Weber,Joachim, Urbatsch,InaL]
通讯作者:
Urbatsch,InaL
Biosynthesis of marine terpenoid natural products
-
批准号:10737210
-
项目类别:
-
资助金额:$50.4万
-
财政年份:2023
-
负责人:GEOFFREY A CHANG
-
依托单位:
Synthetically-evolved and engineered Nanobodies selective for Cb isoforms of PKA
-
批准号:10525796
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2022
-
负责人:GEOFFREY A CHANG
-
依托单位:
Nanobody inhibitors of proton-sensing G protein-coupled receptors
-
批准号:10216432
-
项目类别:
-
资助金额:$15.78万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
-
批准号:10380036
-
项目类别:
-
资助金额:$78.24万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
-
批准号:10184466
-
项目类别:
-
资助金额:$75.92万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
Development of low-cost, field-ready nanobodies against snake venom
-
批准号:10255596
-
项目类别:
-
资助金额:$25.59万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
-
批准号:10594973
-
项目类别:
-
资助金额:$75.99万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
-
批准号:9893680
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2019
-
负责人:GEOFFREY A CHANG
-
依托单位:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
-
批准号:10018872
-
项目类别:
-
资助金额:$19.7万
-
财政年份:2019
-
负责人:GEOFFREY A CHANG
-
依托单位:
Identity, mechanisms and early life impacts of transporter interfering compounds
-
批准号:10179393
-
项目类别:
-
资助金额:$55.86万
-
财政年份:2018
-
负责人:GEOFFREY A CHANG
-
依托单位:
Identity, mechanisms and early life impacts of transporter interfering compounds
-
批准号:10424481
-
项目类别:
-
资助金额:$53.94万
-
财政年份:2018
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure-based optimization of a novel pharmacological chaperone therapy for MPSIIIC
-
批准号:9343249
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2017
-
负责人:GEOFFREY A CHANG
-
依托单位:
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease
-
批准号:9262289
-
项目类别:
-
资助金额:$58.41万
-
财政年份:2014
-
负责人:GEOFFREY A CHANG
-
依托单位:
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease
-
批准号:8843561
-
项目类别:
-
资助金额:$58.41万
-
财政年份:2014
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:8389520
-
项目类别:
-
资助金额:$17.47万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:8707456
-
项目类别:
-
资助金额:$17.24万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:9115590
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:8550059
-
项目类别:
-
资助金额:$17.43万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
GEOFF CHANG PRT-CRYSTALLOGRAPHY OF INTEGRAL MEMBRANE PROTEINS
-
批准号:8362052
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2011
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structural biology and high resolution studies of P-glycoprotein
-
批准号:8536320
-
项目类别:
-
资助金额:$28.47万
-
财政年份:2010
-
负责人:GEOFFREY A CHANG
-
依托单位:
海外基金